Ovarian Cancer

P=N/A, N=35, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

IL-17-responsive, tumor cell-intrinsic inflammatory programming remodels the tumor immune microenvironment toward an immunotherapy-permissive state. These findings establish IL-17-responsive tumor cell inflammatory programming as a mechanistic axis shaping immune checkpoint sensitivity and provide a rationale for biomarker-guided immunotherapy strategies.

Preoperative CA153 and CA199 levels were found to be independent factors influencing ovarian tumour organoid generation. The drug responses of most PDOs to paclitaxel and carboplatin were consistent with the clinical treatment outcomes.

This study discovered three key fibroblast-related genes associated with OC progression and immune cell infiltration. These findings offer potential biomarkers and a theoretical foundation for the development of novel therapeutic strategies for OC.

We also discuss how MEG alterations contribute to the Warburg effect, chemoresistance, and tumor metastasis, which are critical barriers to effective cancer treatment. This synthesis highlights the pivotal role of mitochondrial genetics in cancer biology and positions MEGs as promising targets for innovative anticancer therapies.

Although circulating CAR T-cells became nearly undetectable in peripheral blood by around day 30 after infusion, CAR T-cell infiltration was still detected in resected gastric or ovarian tumor tissues months later. These findings support substantial and durable activity of CLDN18.2 CAR T-cell therapy in gastric cancer with peritoneal metastasis.

P1, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Jun 2027 --> Nov 2028 | Trial primary completion date: Oct 2026 --> Nov 2028

All four RMIs effectively differentiate benign from malignant adnexal masses. RMI-1 offers the highest overall accuracy and specificity, and RMI-2 the highest sensitivity. These indices provide valuable preoperative risk stratification to guide clinical management and referral to specialized care. Institutional resources should inform the choice of RMI.

In the final PRIMA PRO analysis, results confirmed that niraparib first-line maintenance did not negatively affect HRQOL versus placebo. Disease progression caused sustained HRQOL deterioration across arms, emphasizing the clinical importance of extending progression-free survival to preserve patient HRQOL.

In the preclinical study, durable antitumor effect was achieved through combination treatment with Olvi-Vec and cisplatin in mouse model of PROC. Combination therapy of Olvi-Vec and platinum-doublet chemotherapy resulted in a clinically meaningful benefit in the VIRO-15 study, reversing the typical trend of deteriorating PFS, and with clinical reversal of platinum resistance. Olvi-Vec treatment can favorably modify the TME in OC and may explain the apparent reversal of platinum resistance following platinum rechallenge.Trial Registration:ClinicalTrials.gov Identifier: NCT02759588.

Perceived risk was intertwined with cancer worry, and individuals made decisions regarding RRSO based on factors such as perceived risk, control, family planning, hormonal impacts, and recovery. Importantly, healthcare providers exerted both direct and indirect influences on the decision-making process.

Final diagnosis was torsion of a benign ovarian mass with ischemic infarction. Early surgical intervention is essential to avoid such complications.